Exact Mass: 419.1416

A organic heteropentacyclic compound that is 1,2,8,13-tetrahydro-3aH-benzo[b][1,3]oxazolo[3,2-f]phenanthridine which carries oxo groups at positions 2, 8 and 13, methyl group at position 5, hydroxy groups at positions 7 and 12, and a (2R)-butan-2-yl group at position 1. It is a mixture of epimers at the hemiaminal carbon (position 3a).

SCD1 Inhibitor

N-{4-[(2-methoxyethyl)(methyl)amino]phenyl}-2-phenyl-5-(trifluoromethyl)-1,3-oxazole-4-carboxamide

C21H20F3N3O3 (419.1457)

Glycine, L-gamma-glutamyl-2-(1-methyl-4-(nitrosothio)-4-piperidinyl)glycyl-

2-Amino-4-({[(carboxymethyl)-C-hydroxycarbonimidoyl][1-methyl-4-(nitrososulphanyl)piperidin-4-yl]methyl}-C-hydroxycarbonimidoyl)butanoic acid

Perphenazine sulfoxide

2-chloro-10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-5lambda4-phenothiazin-5-one

Cys Asn Pro Ser

(2S)-2-{[(2S)-1-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanoic acid

Cys Asn Ser Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-carbamoylpropanamido]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid

Cys Pro Asn Ser

(2S)-2-[(2S)-2-{[(2S)-1-[(2R)-2-amino-3-sulfanylpropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]-3-hydroxypropanoic acid

Cys Pro Ser Asn

(2S)-2-[(2S)-2-{[(2S)-1-[(2R)-2-amino-3-sulfanylpropanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanamido]-3-carbamoylpropanoic acid

Cys Ser Asn Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

Cys Ser Pro Asn

(2S)-2-{[(2S)-1-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

Perphenazine sulfoxide

7-Hydroxyperphenazine

8-Hydroxy-perphenazine

Perphenazine-N-oxide

Asn Cys Pro Ser

(2S)-2-{[(2S)-1-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanoic acid

Asn Cys Ser Pro

(2S)-1-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-sulfanylpropanamido]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid

Asn Pro Cys Ser

(2S)-2-[(2R)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanamido]-3-hydroxypropanoic acid

Asn Pro Ser Cys

(2R)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanamido]-3-sulfanylpropanoic acid

Asn Ser Cys Pro

(2S)-1-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanamido]-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid

Asn Ser Pro Cys

(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid

Pro Cys Asn Ser

(2S)-2-[(2S)-3-carbamoyl-2-[(2R)-2-[(2S)-pyrrolidin-2-ylformamido]-3-sulfanylpropanamido]propanamido]-3-hydroxypropanoic acid

Pro Cys Ser Asn

(2S)-3-carbamoyl-2-[(2S)-3-hydroxy-2-[(2R)-2-[(2S)-pyrrolidin-2-ylformamido]-3-sulfanylpropanamido]propanamido]propanoic acid

Pro Asn Cys Ser

(2S)-2-[(2R)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-sulfanylpropanamido]-3-hydroxypropanoic acid

Pro Asn Ser Cys

(2R)-2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-hydroxypropanamido]-3-sulfanylpropanoic acid

Pro Ser Cys Asn

(2S)-3-carbamoyl-2-[(2R)-2-[(2S)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-sulfanylpropanamido]propanoic acid

Pro Ser Asn Cys

(2R)-2-[(2S)-3-carbamoyl-2-[(2S)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]-3-sulfanylpropanoic acid

Ser Cys Asn Pro

(2S)-1-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

Ser Cys Pro Asn

(2S)-2-{[(2S)-1-[(2R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-sulfanylpropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

Ser Asn Cys Pro

(2S)-1-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanamido]-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid

Ser Asn Pro Cys

(2R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanoic acid

Ser Pro Cys Asn

(2S)-2-[(2R)-2-{[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}-3-sulfanylpropanamido]-3-carbamoylpropanoic acid

Ser Pro Asn Cys

(2R)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]-3-sulfanylpropanoic acid

METHYL 2-[(3-ETHOXYCARBONYL-PROPYL)-(TOLUENE-4-SULFONYL)-AMINO]-BENZOATE

C21H25NO6S (419.1403)

Prazosin hydrochloride

C19H22ClN5O4 (419.136)

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents Prazosin hydrochloride is a well-tolerated, CNS-active α1-adrenergic receptor antagonist for the research of high blood pressure and alcohol use disorders[1]. Prazosin hydrochloride potently inhibits Norepinephrine (NE)-stimulated 45Ca efflux with an IC50 of 0.15 nM[2].Prazosin hydrochloride inhibits organic cation transporters OCT-1 and OCT-3 with IC50s of 1.8, and 13 μM, respectively[3].

Norfloxacin Succinil

C20H22FN3O6 (419.1493)

z-phe-pna

C23H21N3O5 (419.1481)

Nampt-IN-1

SCD1 inhibitor

N-(4-((2-Methoxyethyl)(methyl)amino)phenyl)-2-phenyl-5-(trifluoromethyl)oxazole-4-carboxamide

C21H20F3N3O3 (419.1457)

Amoxicillin Trihydrate

C16H25N3O8S (419.1362)

A hydrate that is the trihydrate form of amoxicillin; a semisynthetic antibiotic, used either alone or in combination with potassium clavulanate (under the trade name Augmentin) for treatment of a variety of bacterial infections. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic

CHIR-124

4-[(3s)-1-Azabicyclo[2.2.2]oct-3-Ylamino]-3-(1h-Benzimidazol-2-Yl)-6-Chloroquinolin-2(1h)-One

C23H22ClN5O (419.1513)

(3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydrobenzo[g]indazole-7-carboxylic acid

C24H22ClN3O2 (419.14)

4-[(4-Fluorophenyl)-(6-hydroxy-2-methyl-5-thiazolo[3,2-b][1,2,4]triazolyl)methyl]-1-piperazinecarboxylic acid ethyl ester

C19H22FN5O3S (419.1427)

4-(5-Benzenesulfonylamino-1-methyl-1H-benzoimidazol-2-ylmethyl)-benzamidine

C22H21N5O2S (419.1416)

Jadomycin B aglycon

(3aR)-jadomycin A

N-{4-[(1h-Benzotriazol-1-Ylacetyl)(Thiophen-3-Ylmethyl)amino]phenyl}propanamide

C22H21N5O2S (419.1416)

2-ethyl 4-isopropyl 5-{[3-(1,5-dimethyl-1H-pyrazol-4-yl)acryloyl]amino}-3-methyl-2,4-thiophenedicarboxylate

2-[4-(2-Furoyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine hydrochloride

C19H22ClN5O4 (419.136)

1-(4-Methoxyphenyl)-3-[4-methyl-3-(1-piperidinylsulfonyl)phenyl]thiourea

C20H25N3O3S2 (419.1337)

4-[[(4-acetamidophenyl)sulfonylamino]methyl]-N-(3-methoxypropyl)benzamide

6-(1,3-Dioxo-2-isoindolyl)hexanoic acid (4-methyl-2-oxo-1-benzopyran-7-yl) ester

N-[2-[(1,3-benzodioxol-5-ylmethylamino)-oxomethyl]phenyl]-2-ethoxy-3-pyridinecarboxamide

C23H21N3O5 (419.1481)

4-N-[(E)-[2,5-Dimethyl-1-[3-(trifluoromethyl)phenyl]pyrrol-3-yl]methylideneamino]-5-nitropyrimidine-2,4-diamine

C18H16F3N7O2 (419.1318)

N-[(2S,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide

N-[(2S,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide

N-[(2S,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide

N-[(2R,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide

N-[(2R,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide

N-[(2R,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide

N-[(2S,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide

N-[(2R,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-pyridinecarboxamide

N(6)-acetyl-N(2)-(5-phosphopyridoxyl)-L-lysine

C16H26N3O8P (419.1457)

A N(6)-acyl-L-lysine arising from reductive N-alkylation of N(6)-acetyl-L-lysine by pyridoxal-5-phosphate.

hnRNPK-IN-1

C23H21N3O5 (419.1481)

hnRNPK-IN-1 is a heterogeneous nuclear ribonucleoprotein K (hnRNPK) binding ligand with Kd values of 4.6 μM and 2.6 μM measured with SPR and MST, respectively. hnRNPK-IN-1 inhibits c-myc transcription by disrupting the binding of hnRNPK and c-myc promoter. hnRNPK-IN-1 induces Hela cells apoptosis and has strongly anti-tumor activities[1].

11,19-dihydroxy-9-methyl-3-(sec-butyl)-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione

2-{24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁴,²².0¹⁷,²¹]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21)-octaen-23-yl}ethyl acetate

(3s,6s)-11,19-dihydroxy-9-methyl-3-(sec-butyl)-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione

2-[(23s)-24-methyl-5,7,18,20-tetraoxa-24-azahexacyclo[11.11.0.0²,¹⁰.0⁴,⁸.0¹⁴,²².0¹⁷,²¹]tetracosa-1(13),2,4(8),9,11,14(22),15,17(21)-octaen-23-yl]ethyl acetate

(3s)-3-[(2s)-butan-2-yl]-11,19-dihydroxy-9-methyl-5-oxa-2-azapentacyclo[11.8.0.0²,⁶.0⁷,¹².0¹⁵,²⁰]henicosa-1(13),7,9,11,15,17,19-heptaene-4,14,21-trione